GlassScriptPhysician profile
Cp Dunbar
NPI 1205821865
$7,479.01
in general payments reported to CMS, 2019-2025
44 companies · $908 in 2025
The $908 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $764 · 2020: $572 · 2021: $1,385 · 2022: $1,218 · 2023: $1,552 · 2024: $1,079 · 2025: $908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,538.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,147.60 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Forte Bio-Pharma LLC | $726.20 | 2020-2025 | Prolate, Nalocet, Tanlor |
| Glaxosmithkline, LLC. | $652.33 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $507.88 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $498.04 | 2019-2024 | Xifaxan, Trulance |
| Novo Nordisk INC | $387.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $351.19 | 2022-2024 | |
| Pfizer INC. | $341.49 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $295.73 | 2021-2023 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.09 | 2019-2023 | |
| Lilly USA, LLC | $259.51 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Insulet Corporation | $252.56 | 2019-2024 | Omnipod |
| Otsuka America Pharmaceutical, INC. | $176.13 | 2022-2023 | Rexulti, Abilify Maintena |
| Optinose US, INC. | $163.10 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $153.77 | 2019-2021 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $152.07 | 2019-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $125.41 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $99.93 | 2021 | |
| Merck Sharp & Dohme LLC | $87.58 | 2020-2021 | |
| Biodelivery Sciences International, INC. | $73.34 | 2019 | |
| Hikma Pharmaceuticals USA | $70.61 | 2022 | |
| Dexcom, INC. | $64.44 | 2021-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $62.04 | 2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $53.24 | 2019-2022 | |
| Harmony Biosciences LLC | $46.98 | 2025 | |
| Janssen Pharmaceuticals, INC | $46.28 | 2019-2023 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.39 | 2022 | |
| Virtus Pharmaceuticals LLC | $40.81 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.42 | 2022 | |
| Indivior INC. | $34.46 | 2024-2025 | Sublocade |
| Allergan, INC. | $26.01 | 2020 | |
| Lundbeck LLC | $24.18 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $22.80 | 2020 | |
| Corcept Therapeutics | $20.64 | 2024 | Korlym |
| Tris Pharma INC | $20.61 | 2023 | Dyanavel Xr |
| Jazz Pharmaceuticals INC. | $20.25 | 2019 | |
| Stryker Corporation | $19.07 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Edwards Lifesciences Corporation | $17.49 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Vital Connect, INC | $15.05 | 2023 | Vitalpatch Rtm |
| Astellas Pharma US INC | $14.23 | 2021 | |
| Amarin Pharma, INC. | $14.22 | 2020 | |
| Kaleo, INC. | $11.36 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.01 | 2019 | |
| Sanofi Pasteur INC. | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cp Dunbar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.